Celldex Therapeutics reported $78.5M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agenus USD 38.52M 3.2M Mar/2026
Amgen USD 541M 1000K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celldex Therapeutics USD 78.5M 11.93M Jun/2026
Glaxosmithkline GBP 4.05B 20.6M Mar/2026
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Northwest Biotherapeutics USD 1.61B 88.6M Mar/2026
Pfizer USD 5.7B 0 Jun/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Roche Holding CHF 796.77M 1.15M Jun/2026